FDA Approves Elraglusib Oral Formulation for Clinical Trials
- Clinical Development Phase: Actuate Therapeutics has received FDA clearance to initiate a Phase 1/2 study of the oral formulation of Elraglusib in advanced cancer patients in the second half of 2026, aiming to enhance overall drug exposure and improve patient survival rates.
- Combination Potential: The company is exploring the combination of Elraglusib with RAS inhibitors, with early preclinical data indicating potential synergy in RAS-driven cancers, positioning it as a backbone agent in future treatment regimens and broadening clinical applications.
- New Board Member: Industry veteran Martin Huber, MD, joins Actuate's Board of Directors, bringing extensive oncology drug development experience that will strengthen the company's strategic execution capabilities as it advances the oral formulation of Elraglusib.
- Enhanced Patient Convenience: By transitioning to an oral formulation, Actuate aims to improve patient convenience and expand the clinical utility of Elraglusib across multiple oncology indications, which is expected to significantly enhance patient treatment experience and adherence.
Trade with 70% Backtested Accuracy
Analyst Views on ACTU
About ACTU
About the author
FDA Approves Elraglusib Oral Formulation for Clinical Trials
- Clinical Development Phase: Actuate Therapeutics has received FDA clearance to initiate a Phase 1/2 study of the oral formulation of Elraglusib in advanced cancer patients in the second half of 2026, aiming to enhance overall drug exposure and improve patient survival rates.
- Combination Potential: The company is exploring the combination of Elraglusib with RAS inhibitors, with early preclinical data indicating potential synergy in RAS-driven cancers, positioning it as a backbone agent in future treatment regimens and broadening clinical applications.
- New Board Member: Industry veteran Martin Huber, MD, joins Actuate's Board of Directors, bringing extensive oncology drug development experience that will strengthen the company's strategic execution capabilities as it advances the oral formulation of Elraglusib.
- Enhanced Patient Convenience: By transitioning to an oral formulation, Actuate aims to improve patient convenience and expand the clinical utility of Elraglusib across multiple oncology indications, which is expected to significantly enhance patient treatment experience and adherence.
Actuate Therapeutics Reports Positive Clinical Data for Elraglusib
- Clinical Trial Results: Actuate Therapeutics published new data in Nature Medicine from the Phase 2 trial of Elraglusib combined with GnP for metastatic pancreatic cancer, showing a median overall survival increase of 10.1 months to 17.3 months, significantly outperforming the 7.2 months for GnP alone, indicating the drug's potential in pancreatic cancer treatment.
- Survival Rate Improvement: The one-year survival rate for the combination therapy group was 44.1%, compared to just 22.3% for the GnP alone group, suggesting that the use of Elraglusib significantly enhances patient survival chances and could change treatment standards for pancreatic cancer.
- Safety Assessment: While the safety profile of the Elraglusib/GnP combination was generally manageable, common Grade 3 or higher adverse events included neutropenia, anemia, and fatigue, indicating the need for careful monitoring of patient tolerance in clinical applications.
- Positive Market Reaction: Following the data release, ACTU's stock price rose by 14.27% to close at $2.08, reflecting investor confidence in the drug's potential, with further gains of 2.88% in after-hours trading, indicating optimistic market expectations for its future development.
Actuate Therapeutics Announces Encouraging Phase II Results for Salivary Gland Cancers
Positive Study Results: Actuate Therapeutics reported favorable outcomes from a Phase II study of elraglusib combined with carboplatin or cisplatin for advanced metastatic salivary gland cancers, showing a median overall survival of 18.6 months.
Patient Demographics and Survival Rates: The study included 47% adenoid cystic carcinoma (ACC) and 53% non-ACC patients, with non-ACC patients experiencing a median overall survival of 27.8 months.
Progression-Free Survival: The median progression-free survival was 6.4 months, with only 27% of patients remaining progression-free at one year, contrasting with historical estimates for ACC and non-ACC.
Market Reaction: Following the announcement, Actuate shares increased by over 4% in pre-market trading, closing at $7.52, reflecting a 1.35% rise from the previous day.
HC Wainwright & Co. Affirms Buy Rating for Actuate Therapeutics, Keeps $20 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Actuate Therapeutics Reveals Pricing for $15.0 Million Public Stock Offering
Public Offering Announcement: Actuate Therapeutics, Inc. has priced an underwritten public offering of 2,142,858 shares of common stock at $7.00 per share, aiming to raise approximately $15 million for working capital and corporate purposes.
Use of Proceeds: The company plans to utilize the net proceeds from the offering for general corporate needs, with the offering expected to close on September 11, 2025, pending customary closing conditions.
Company Focus: Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for challenging cancers, with its lead drug, elraglusib, targeting pathways that promote tumor growth and resistance to conventional treatments.
Forward-Looking Statements: The press release includes forward-looking statements regarding the offering's timing and completion, emphasizing the inherent risks and uncertainties that could affect actual results.
Actuate Therapeutics Analyst Starts Coverage Positively; Check Out Tuesday's Top 3 Initiations
Analyst Ratings Updates: Top Wall Street analysts have revised their outlooks on several companies, with a focus on upgrades and new coverage initiations.
Actuate Therapeutics Coverage: B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics (ACTU) with a Buy rating and a price target of $20, while the stock closed at $7.98.
Gyre Therapeutics Coverage: HC Wainwright & Co. analyst Matthew Keller also initiated coverage on Gyre Therapeutics (GYRE) with a Buy rating and a price target of $18, closing at $8.18.
CareDx Coverage: William Blair analyst Andrew Brackmann started coverage on CareDx (CDNA) with a Market Perform rating, with shares closing at $12.75.
FDA Approves Elraglusib Oral Formulation for Clinical Trials
- Clinical Development Phase: Actuate Therapeutics has received FDA clearance to initiate a Phase 1/2 study of the oral formulation of Elraglusib in advanced cancer patients in the second half of 2026, aiming to enhance overall drug exposure and improve patient survival rates.
- Combination Potential: The company is exploring the combination of Elraglusib with RAS inhibitors, with early preclinical data indicating potential synergy in RAS-driven cancers, positioning it as a backbone agent in future treatment regimens and broadening clinical applications.
- New Board Member: Industry veteran Martin Huber, MD, joins Actuate's Board of Directors, bringing extensive oncology drug development experience that will strengthen the company's strategic execution capabilities as it advances the oral formulation of Elraglusib.
- Enhanced Patient Convenience: By transitioning to an oral formulation, Actuate aims to improve patient convenience and expand the clinical utility of Elraglusib across multiple oncology indications, which is expected to significantly enhance patient treatment experience and adherence.
Actuate Therapeutics Reports Positive Clinical Data for Elraglusib
- Clinical Trial Results: Actuate Therapeutics published new data in Nature Medicine from the Phase 2 trial of Elraglusib combined with GnP for metastatic pancreatic cancer, showing a median overall survival increase of 10.1 months to 17.3 months, significantly outperforming the 7.2 months for GnP alone, indicating the drug's potential in pancreatic cancer treatment.
- Survival Rate Improvement: The one-year survival rate for the combination therapy group was 44.1%, compared to just 22.3% for the GnP alone group, suggesting that the use of Elraglusib significantly enhances patient survival chances and could change treatment standards for pancreatic cancer.
- Safety Assessment: While the safety profile of the Elraglusib/GnP combination was generally manageable, common Grade 3 or higher adverse events included neutropenia, anemia, and fatigue, indicating the need for careful monitoring of patient tolerance in clinical applications.
- Positive Market Reaction: Following the data release, ACTU's stock price rose by 14.27% to close at $2.08, reflecting investor confidence in the drug's potential, with further gains of 2.88% in after-hours trading, indicating optimistic market expectations for its future development.
Actuate Therapeutics Announces Encouraging Phase II Results for Salivary Gland Cancers
Positive Study Results: Actuate Therapeutics reported favorable outcomes from a Phase II study of elraglusib combined with carboplatin or cisplatin for advanced metastatic salivary gland cancers, showing a median overall survival of 18.6 months.
Patient Demographics and Survival Rates: The study included 47% adenoid cystic carcinoma (ACC) and 53% non-ACC patients, with non-ACC patients experiencing a median overall survival of 27.8 months.
Progression-Free Survival: The median progression-free survival was 6.4 months, with only 27% of patients remaining progression-free at one year, contrasting with historical estimates for ACC and non-ACC.
Market Reaction: Following the announcement, Actuate shares increased by over 4% in pre-market trading, closing at $7.52, reflecting a 1.35% rise from the previous day.
HC Wainwright & Co. Affirms Buy Rating for Actuate Therapeutics, Keeps $20 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Actuate Therapeutics Reveals Pricing for $15.0 Million Public Stock Offering
Public Offering Announcement: Actuate Therapeutics, Inc. has priced an underwritten public offering of 2,142,858 shares of common stock at $7.00 per share, aiming to raise approximately $15 million for working capital and corporate purposes.
Use of Proceeds: The company plans to utilize the net proceeds from the offering for general corporate needs, with the offering expected to close on September 11, 2025, pending customary closing conditions.
Company Focus: Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for challenging cancers, with its lead drug, elraglusib, targeting pathways that promote tumor growth and resistance to conventional treatments.
Forward-Looking Statements: The press release includes forward-looking statements regarding the offering's timing and completion, emphasizing the inherent risks and uncertainties that could affect actual results.
Actuate Therapeutics Analyst Starts Coverage Positively; Check Out Tuesday's Top 3 Initiations
Analyst Ratings Updates: Top Wall Street analysts have revised their outlooks on several companies, with a focus on upgrades and new coverage initiations.
Actuate Therapeutics Coverage: B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics (ACTU) with a Buy rating and a price target of $20, while the stock closed at $7.98.
Gyre Therapeutics Coverage: HC Wainwright & Co. analyst Matthew Keller also initiated coverage on Gyre Therapeutics (GYRE) with a Buy rating and a price target of $18, closing at $8.18.
CareDx Coverage: William Blair analyst Andrew Brackmann started coverage on CareDx (CDNA) with a Market Perform rating, with shares closing at $12.75.
